FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093653710> ?p ?o ?g. }

• W3093653710 endingPage "491" @default.
• W3093653710 startingPage "485" @default.
• W3093653710 abstract "Despite the expansion of immune checkpoint inhibitor (ICI) indications, the relationship between ICI dose and toxicity or response is not well established. To understand this correlation, we performed a meta-analysis of ICI trials that used dose escalation.We searched PubMed and abstracts presented at (inter)national meetings for trials using FDA-approved ICIs. The reported rates of grade 3-5 adverse events (G3-5 AE), immune-related adverse events (irAE), and response were correlated with doses within each ICI using marginal exact generalized linear models.A total of 74 trials (7,469 patients) published between January 2010 and January 2017 were included. For ipilimumab, the incidence of G3-5 AEs was 34% with a significant 27% reduced risk in lower doses (P = 0.002). However, no relationship was observed between dose and irAEs or response. For nivolumab, the incidence of G3-5 AEs was 20.1% which was lower in non-small cell lung cancer (NSCLC) compared with renal cell carcinoma (RCC) or melanoma (P ≤ 0.05) with no dose-toxicity relationship. In melanoma and NSCLC, a dose-response association was observed, which was not observed in RCC. For pembrolizumab, the incidence of G3-5 AEs was 13.3%, which was lower in melanoma compared with NSCLC (P = 0.03) with no dose-toxicity relationship. In melanoma, lower dose levels correlated with decreased odds of response (P = 0.01), a relationship that was not observed in NSCLC.Our analysis shows a lack of consistent dose-toxicity or dose-response correlation with ICIs. Therefore, dose escalation is not an appropriate design to conduct ICI studies. Here we present an innovative trial design for immune-modulating agents." @default.
• W3093653710 created "2020-10-29" @default.
• W3093653710 creator A5025486627 @default.
• W3093653710 creator A5026861780 @default.
• W3093653710 creator A5030292463 @default.
• W3093653710 creator A5040159842 @default.
• W3093653710 creator A5046416890 @default.
• W3093653710 creator A5048143305 @default.
• W3093653710 creator A5059854267 @default.
• W3093653710 creator A5071788399 @default.
• W3093653710 creator A5080783554 @default.
• W3093653710 date "2021-01-15" @default.
• W3093653710 modified "2023-10-13" @default.
• W3093653710 title "Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors" @default.
• W3093653710 cites W2066671159 @default.
• W3093653710 cites W2109653150 @default.
• W3093653710 cites W2143163879 @default.
• W3093653710 cites W2156748975 @default.
• W3093653710 cites W2209812019 @default.
• W3093653710 cites W2342481353 @default.
• W3093653710 cites W2347055022 @default.
• W3093653710 cites W2549481046 @default.
• W3093653710 cites W2603690292 @default.
• W3093653710 cites W2783137027 @default.
• W3093653710 cites W2803744378 @default.
• W3093653710 cites W2805103957 @default.
• W3093653710 cites W2890930659 @default.
• W3093653710 cites W2893321040 @default.
• W3093653710 cites W2900174742 @default.
• W3093653710 cites W2912537198 @default.
• W3093653710 cites W3037489831 @default.
• W3093653710 doi "https://doi.org/10.1158/1078-0432.ccr-20-2669" @default.
• W3093653710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33082209" @default.
• W3093653710 hasPublicationYear "2021" @default.
• W3093653710 type Work @default.
• W3093653710 sameAs 3093653710 @default.
• W3093653710 citedByCount "4" @default.
• W3093653710 countsByYear W30936537102021 @default.
• W3093653710 countsByYear W30936537102022 @default.
• W3093653710 countsByYear W30936537102023 @default.
• W3093653710 crossrefType "journal-article" @default.
• W3093653710 hasAuthorship W3093653710A5025486627 @default.
• W3093653710 hasAuthorship W3093653710A5026861780 @default.
• W3093653710 hasAuthorship W3093653710A5030292463 @default.
• W3093653710 hasAuthorship W3093653710A5040159842 @default.
• W3093653710 hasAuthorship W3093653710A5046416890 @default.
• W3093653710 hasAuthorship W3093653710A5048143305 @default.
• W3093653710 hasAuthorship W3093653710A5059854267 @default.
• W3093653710 hasAuthorship W3093653710A5071788399 @default.
• W3093653710 hasAuthorship W3093653710A5080783554 @default.
• W3093653710 hasBestOaLocation W30936537101 @default.
• W3093653710 hasConcept C120665830 @default.
• W3093653710 hasConcept C121332964 @default.
• W3093653710 hasConcept C121608353 @default.
• W3093653710 hasConcept C126322002 @default.
• W3093653710 hasConcept C143998085 @default.
• W3093653710 hasConcept C197934379 @default.
• W3093653710 hasConcept C2776256026 @default.
• W3093653710 hasConcept C2777472916 @default.
• W3093653710 hasConcept C2777658100 @default.
• W3093653710 hasConcept C2777701055 @default.
• W3093653710 hasConcept C2780030458 @default.
• W3093653710 hasConcept C2780057760 @default.
• W3093653710 hasConcept C2781433595 @default.
• W3093653710 hasConcept C29730261 @default.
• W3093653710 hasConcept C502942594 @default.
• W3093653710 hasConcept C535046627 @default.
• W3093653710 hasConcept C61511704 @default.
• W3093653710 hasConcept C71924100 @default.
• W3093653710 hasConceptScore W3093653710C120665830 @default.
• W3093653710 hasConceptScore W3093653710C121332964 @default.
• W3093653710 hasConceptScore W3093653710C121608353 @default.
• W3093653710 hasConceptScore W3093653710C126322002 @default.
• W3093653710 hasConceptScore W3093653710C143998085 @default.
• W3093653710 hasConceptScore W3093653710C197934379 @default.
• W3093653710 hasConceptScore W3093653710C2776256026 @default.
• W3093653710 hasConceptScore W3093653710C2777472916 @default.
• W3093653710 hasConceptScore W3093653710C2777658100 @default.
• W3093653710 hasConceptScore W3093653710C2777701055 @default.
• W3093653710 hasConceptScore W3093653710C2780030458 @default.
• W3093653710 hasConceptScore W3093653710C2780057760 @default.
• W3093653710 hasConceptScore W3093653710C2781433595 @default.
• W3093653710 hasConceptScore W3093653710C29730261 @default.
• W3093653710 hasConceptScore W3093653710C502942594 @default.
• W3093653710 hasConceptScore W3093653710C535046627 @default.
• W3093653710 hasConceptScore W3093653710C61511704 @default.
• W3093653710 hasConceptScore W3093653710C71924100 @default.
• W3093653710 hasIssue "2" @default.
• W3093653710 hasLocation W30936537101 @default.
• W3093653710 hasLocation W30936537102 @default.
• W3093653710 hasOpenAccess W3093653710 @default.
• W3093653710 hasPrimaryLocation W30936537101 @default.
• W3093653710 hasRelatedWork W10495966 @default.
• W3093653710 hasRelatedWork W10640851 @default.
• W3093653710 hasRelatedWork W11019453 @default.
• W3093653710 hasRelatedWork W11093380 @default.
• W3093653710 hasRelatedWork W13151608 @default.
• W3093653710 hasRelatedWork W14019567 @default.

• next